Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus

Archives of Dermatological Research

Volumn 299, Issue 9, 2007, Pages 461-465

  Martínez Abundis, Esperanza ^a,b   Reynoso Von Drateln, Claudia ^a   Hernández Salazar, Eduardo ^a   González Ortiz, Manuel ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b NONE   (Mexico)

Author keywords

Etanercept; Insulin; Psoriasis

Indexed keywords

ETANERCEPT; INSULIN;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; ERYTHEMA; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; INFORMED CONSENT; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PSORIASIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK; RISK FACTOR;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATOLOGIC AGENTS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE; MALE; PILOT PROJECTS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 35148818401     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-007-0784-3     Document Type: Article

References (26)

1. Bloomgarden Z (2003) Inflammation and insulin resistance. Diabetes Care 26:1619-1623
2. Cottet S, Dupraz P, Hamburger F, Dolci W, Jaquet M, Thorens B (2002) cFLIP Protein prevents tumor necrosis factor-[alpha]-mediated induction of caspase-8-dependent apoptosis in insulin-secreting [beta]Tc-Tet cells. Diabetes 51:1805-1814
3. Culy C, Keating G (2002) Etanercept. Drugs 2:2493-2437
4. DeFronzo RA, Tobin J, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 6:E214-E223
5. Gellfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735-1741
6. González-Ortiz M, Martínez-Abundis E, Balcázar- Muñoz B, Robles-Cervantes J (2001) Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects. Horm Metab Res 33:250-253
7. González-Ortiz M, Martínez-Abundis E, Lifshitz A (1998) Insulin sensitivity and sex steroid hormone levels during the menstrual cycle in healthy women with non-insulin-dependent diabetic parents. Gynecol Obstet Invest 46:187-190
8. Gottlieb A (2001) Psoriasis: immunopathology and immunomodulation. Dermatol Clin 19:649-655
9. Hotamisligil G, Shargill N, Spiegelman B (1993) Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:7-90
10. Iyer S, Yamauchi P, Lowe N (2002) Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 146:118-121
11. Jeyasseelan L, Rao P (1989) Methods of determining sample sizes in clinical trials. Indian Pediatr 26:115-121
12. Kormeili T, Lowe N, Yamauchi P (2004) Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies: US experiencies. Br J Dermatol 151:3-15
13. Korth-Bradley JM, Sue-Rubin A, Hanna RK, Simcoe DK, Lebsack ME (2000) The pharmacokinetics of etanercept in healthy volunteer. Ann Pharmacother 34:161-164
14. Krueger G, Callis K (2004) Potential of tumor necrosis factor inhibitor in psoriasis and psoriatic arthritis. Arch Dermatol 140:218-225
15. LaDuca J, Gaspari A (2001) Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 19:617-635
16. Ludwig R, Herzog C, Rostock A, Ochsendorf F, Zollner T, Thaci D, Kaufmann R, Vogl T, Boehncke W (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 56:2761-2627
17. Miyazaki Y, Pipek R, Mandarino L, DeFronzo R (2003) Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients. Int J Obes 27:88-94
18. Ofei F, Hurel S, Newkirk J, Sopwith M Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881-885
19. Pakala S, Chivetta M, Kelly C, Katz J (1999) In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 189:1053-1062
20. Paquot N, Castillo M, Lefèbvre P, Scheen A (2000) No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316-1319
21. Rask-Madsen C, Domínguez H, Ihlemann N, Hermann T, Køber L, Torp-Pedersen C (2002) Tumor necrosis factor-[alpha] inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilatation in humans. Circulation 108:1815-1821
22. Spranger-Joachim K, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH (2003) Inflammatory cytokines and the risk to develop type 2 diabetes. Results of the prospective population-based european prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes 52:812-817
23. von Eckardstein A, Schulte H, Assmann G (2000) Risk for diabetes mellitus in middle-aged caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. J Clin Endocrinol Metab 85:3101-3108
24. Weir G, Laybutt D, Kaneto H, Bonner-Weir S, Sharma A (2001) Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 50:S154-S159
25. Winkler G, Lakatos P, Salamon F, Speer G, Baranyi E, Melczer Z, Karoly C (1999) Response to Fernandez-Real et al. Contribution of tumor necrosis factor-alpha in insulin resistance in patients with android type obesity. Diabetes Care 22:870
26. Yoshitaka S, Hiroaki D, Shuji M, Masayuki I, Satoshi T, Tomohiko T, Toshihiko I (2004) Infliximab (anti-tnf alpha antibody) improved insulin resistance in rheumatoid arthritis patients. Diabetes 53:A160-A161